Compass Therapeutics Inc. (CMPX): Price and Financial Metrics


Compass Therapeutics Inc. (CMPX): $3.99

-0.01 (-0.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CMPX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CMPX Stock Price Chart Interactive Chart >

Price chart for CMPX

CMPX Price/Volume Stats

Current price $3.99 52-week high $5.65
Prev. close $4.00 52-week low $1.25
Day low $3.88 Volume 390,000
Day high $4.01 Avg. volume 372,471
50-day MA $4.59 Dividend yield N/A
200-day MA $3.21 Market Cap 503.50M

Compass Therapeutics Inc. (CMPX) Company Bio


Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. immuno-oncology product candidates include a clinical-stage monoclonal antibody targeting solid tumors, a novel bispecific targeting PD-1 and PD-L1, and a portfolio of bispecific and monoclonal antibodies at various stages of pre-clinical development. The company was founded by Thomas J. Schuetz on March 20, 2018 and is headquartered in Boston, MA.


CMPX Latest News Stream


Event/Time News Detail
Loading, please wait...

CMPX Latest Social Stream


Loading social stream, please wait...

View Full CMPX Social Stream

Latest CMPX News From Around the Web

Below are the latest news stories about COMPASS THERAPEUTICS INC that investors may wish to consider to help them evaluate CMPX as an investment opportunity.

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the second- and third- line settings; at least one response was observed in each of the four anatomical subtypes of BTC Sub-group analysis showed that an ORR of 63.6% was observed in the 11 patients treated in the second-line setting compared with an ORR of 14.9% in the 13 patients treated in the third-line

Yahoo | January 19, 2023

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

BOSTON, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”; Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the first patient has been dosed in the Phase 2 U.S. study of CTX-009 in patients with metastatic colorectal cancer who are being treated in the third- and fourth-line setting. Patients enrolled in the study have received at least two pr

Yahoo | January 6, 2023

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

BOSTON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that updated results from the ongoing Phase 2 study of CTX-009 combined with paclitaxel in patients with biliary tract cancer (BTC) will be presented at a poster session of the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposiu

Yahoo | December 15, 2022

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

First patient dosed in Phase 1b study of CTX-471 in combination with KEYTRUDA® in cancers of the lung, head and neck, as well as melanomaIn the first part of this Phase 1b study, CTX-471 was dosed as a monotherapy and demonstrated signs of activity in patients with various metastatic or locally advanced solid tumors who initially benefited from a checkpoint inhibitorThe study is designed to evaluate the potential of CTX-471 in combination with KEYTRUDA® to address treatment resistance and improv

Yahoo | December 1, 2022

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which is taking place at the Lotte New York Palace November 29 – December 1, 2022. Presentation details: Date: Thursday, December 1, 2022Time: 8:50 – 9:10 AM ET Webcast: the link will be available o

Yahoo | November 22, 2022

Read More 'CMPX' Stories Here

CMPX Price Returns

1-mo -22.52%
3-mo -0.25%
6-mo 50.00%
1-year 157.42%
3-year N/A
5-year N/A
YTD -20.68%
2022 58.68%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6339 seconds.